Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.
1
Study Matches
Site for EA9161: A Randomized Phase III Study of the addition of
Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib
and Obinutuzumab in Untreated Younger Patients with
Chronic Lymphocytic Leukemia (CLL)
The is a drug study to compare the progression free
survival of the three drug combination Ibrutinib-Obinutuzumab-Venetoclax (IOV) to Ibrutinib-Obinutuzumab (IO) in untreated CLL patients younger than 70 years of age.
Diagnosis of CLL according to the NCI/IWCLL criteria or SLL according to the WHO criteria Negative FISH analysis for t(11;14)(IgH/CCND1) on peripheral blood or tissue biopsy Age ≥ 18 years and < 70. ECOG performance status between 0-2. Life expectancy of ≥ 12 months.
Exclusion Criteria:
No deletion of 17p13 on cytogenetic analysis by FISH No active hemolytic anemia requiring immunosuppressive therapy or other pharmacologic treatment. No current use of corticosteroids. No previous autoimmune complications No other active primary malignancy